Loading…
Shanghai maker of cell-culture media and bioprocessing consumables used to manufacture biologic drugs and vaccines.
Shanghai maker of cell-culture media and bioprocessing consumables used to manufacture biologic drugs and vaccines.
Customers qualify its media into their production process for a biologic drug and then reorder for as long as that drug is made, so a successful launch in China brings repeat purchases; it also earns service fees for helping develop the process.
In one line: A small Chinese Cytiva/Thermo Fisher bioprocess unit.
Moat: narrow (switching costs, process know-how). Culture-media formulas are qualified into a customer's manufacturing process, discouraging supplier changes.
Headquarters: Shanghai, China · Employees: 367
Size Shanghai OPM Biosciences (688293.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.35B, the 1800th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥63.06 on 6 Nov 2026.
Performance Over six months the shares gained 25.5%, against -13.2% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 133.0% over the last twelve months (peer median +17.1%); the operating margin is 10.9% (peer median 2.8%).
Valuation It trades at 50.3× forward earnings against a peer median of 19.2× (3rd most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points below its cost of capital (7.6% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥822M | CN¥353M | CN¥296M | CN¥243M | CN¥294M |
| Revenue growth | — | +19% | +22% | -17% | — |
| Gross profit | CN¥452M | CN¥159M | CN¥138M | CN¥126M | CN¥173M |
| EBITDA | n/a | CN¥87.2M | CN¥54.6M | CN¥61.7M | CN¥128M |
| Net income | CN¥41.1M | CN¥41.7M | CN¥21.1M | CN¥54.0M | CN¥105M |
| Free cash flow | CN¥177M | CN¥55.5M | -CN¥47.6M | -CN¥18.3M | -CN¥32.5M |
| Capital expenditure | CN¥26.9M | CN¥56.1M | CN¥121M | CN¥77.5M | CN¥147M |
| Total debt | CN¥314M | CN¥57.0M | CN¥65.3M | CN¥69.4M | CN¥91.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai OPM Biosciences 688293.SS | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Fujifilm 4901.T | $24.9B | +14% | +7% | 10% | 14.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688293.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.1% | -5.6% | 6th lowest of 21 |
| 6-month return | +25.5% | -13.2% | 3rd highest of 21 |
| Distance from 52-week high | -28.8% | -36.2% | 8th highest of 21 |
| Revenue growth (TTM) | +133.0% | +17.1% | 2nd highest of 18 |
| Operating margin | 10.9% | 2.8% | 8th highest of 18 |
| Forward P/E | 50.3× | 19.2× | 3rd most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 26.1% | -1.1% | most demanding of 7 |
| Growth delivered (Del g) | +23.1% | +8.3% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | +3.1 pp | -17.8 pp | 2nd most demanding of 7 |
| ROIC minus cost of capital | -1.7 pp | -5.6 pp | 6th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% | -5.3% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 19.7× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |